Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroprotective Agents | 11 | 2022 | 941 | 3.280 |
Why?
|
| Intracranial Hemorrhages | 7 | 2021 | 855 | 2.050 |
Why?
|
| Reperfusion Injury | 6 | 2022 | 1027 | 1.220 |
Why?
|
| NF-E2-Related Factor 2 | 4 | 2021 | 379 | 1.120 |
Why?
|
| Blood-Brain Barrier | 4 | 2019 | 1018 | 0.890 |
Why?
|
| Iron Chelating Agents | 2 | 2020 | 139 | 0.860 |
Why?
|
| Brain Ischemia | 8 | 2022 | 3264 | 0.800 |
Why?
|
| Brain Injuries | 5 | 2021 | 2029 | 0.770 |
Why?
|
| Endothelial Cells | 9 | 2021 | 3482 | 0.760 |
Why?
|
| Pericytes | 3 | 2019 | 293 | 0.690 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 116 | 0.640 |
Why?
|
| Intracellular Space | 1 | 2019 | 210 | 0.630 |
Why?
|
| Oleanolic Acid | 1 | 2016 | 43 | 0.550 |
Why?
|
| Microvessels | 2 | 2017 | 544 | 0.540 |
Why?
|
| Oligopeptides | 2 | 2020 | 1188 | 0.510 |
Why?
|
| Antioxidants | 4 | 2022 | 1658 | 0.500 |
Why?
|
| Aniline Compounds | 1 | 2019 | 986 | 0.500 |
Why?
|
| Tetrazoles | 2 | 2017 | 834 | 0.490 |
Why?
|
| Iron | 2 | 2020 | 1774 | 0.480 |
Why?
|
| Stroke | 7 | 2023 | 9975 | 0.470 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2023 | 1018 | 0.470 |
Why?
|
| Imidazoles | 1 | 2019 | 1206 | 0.450 |
Why?
|
| Disease Models, Animal | 15 | 2023 | 18027 | 0.380 |
Why?
|
| Hematopoiesis | 1 | 2019 | 2073 | 0.340 |
Why?
|
| Cerebrovascular Circulation | 6 | 2023 | 2732 | 0.340 |
Why?
|
| Mitochondria | 3 | 2020 | 3513 | 0.320 |
Why?
|
| Warfarin | 1 | 2016 | 1497 | 0.300 |
Why?
|
| Triterpenes | 2 | 2018 | 80 | 0.290 |
Why?
|
| Cerebral Hemorrhage | 5 | 2023 | 2647 | 0.290 |
Why?
|
| Mice | 23 | 2023 | 81154 | 0.290 |
Why?
|
| Glucose | 3 | 2022 | 4398 | 0.280 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2019 | 3389 | 0.280 |
Why?
|
| Oxygen | 2 | 2022 | 4189 | 0.280 |
Why?
|
| Carotenoids | 2 | 2020 | 623 | 0.280 |
Why?
|
| Reactive Oxygen Species | 5 | 2022 | 2077 | 0.270 |
Why?
|
| Animals | 29 | 2023 | 168660 | 0.260 |
Why?
|
| Brain | 10 | 2022 | 26345 | 0.260 |
Why?
|
| Cyclodextrins | 1 | 2022 | 57 | 0.220 |
Why?
|
| Behavior, Animal | 3 | 2021 | 1880 | 0.210 |
Why?
|
| Hemin | 2 | 2019 | 50 | 0.210 |
Why?
|
| Benzamidines | 1 | 2021 | 25 | 0.210 |
Why?
|
| Cell Death | 4 | 2020 | 1705 | 0.200 |
Why?
|
| Apoptosis | 6 | 2022 | 9718 | 0.200 |
Why?
|
| Guanabenz | 1 | 2021 | 6 | 0.200 |
Why?
|
| CADASIL | 1 | 2022 | 84 | 0.200 |
Why?
|
| Guanidines | 1 | 2021 | 193 | 0.190 |
Why?
|
| Anticoagulants | 1 | 2016 | 4599 | 0.190 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2021 | 179 | 0.180 |
Why?
|
| Clonidine | 1 | 2021 | 164 | 0.180 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2021 | 87 | 0.180 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2020 | 242 | 0.180 |
Why?
|
| Cells, Cultured | 5 | 2021 | 19232 | 0.180 |
Why?
|
| Cell Survival | 3 | 2021 | 5881 | 0.180 |
Why?
|
| Cortical Spreading Depression | 1 | 2023 | 276 | 0.180 |
Why?
|
| Collagenases | 2 | 2017 | 228 | 0.180 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2019 | 11 | 0.180 |
Why?
|
| Hydrogen Peroxide | 2 | 2020 | 730 | 0.170 |
Why?
|
| Ischemic Attack, Transient | 2 | 2023 | 934 | 0.170 |
Why?
|
| rap GTP-Binding Proteins | 1 | 2019 | 28 | 0.170 |
Why?
|
| Ferrous Compounds | 1 | 2019 | 42 | 0.170 |
Why?
|
| Reperfusion | 1 | 2020 | 283 | 0.170 |
Why?
|
| Colony-Forming Units Assay | 1 | 2019 | 355 | 0.160 |
Why?
|
| Free Radical Scavengers | 1 | 2019 | 216 | 0.160 |
Why?
|
| Stem Cell Factor | 1 | 2019 | 219 | 0.160 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2019 | 204 | 0.160 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2017 | 298 | 0.160 |
Why?
|
| Hematoma | 2 | 2023 | 758 | 0.160 |
Why?
|
| Infarction, Middle Cerebral Artery | 4 | 2023 | 476 | 0.160 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 1 | 2017 | 11 | 0.150 |
Why?
|
| Choroidal Neovascularization | 1 | 2021 | 343 | 0.150 |
Why?
|
| Collagen Type IV | 1 | 2017 | 140 | 0.140 |
Why?
|
| Eye | 1 | 2021 | 727 | 0.140 |
Why?
|
| Signal Transduction | 2 | 2019 | 23398 | 0.140 |
Why?
|
| Neurons, Afferent | 1 | 2019 | 504 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2021 | 10477 | 0.130 |
Why?
|
| Random Allocation | 2 | 2017 | 2429 | 0.130 |
Why?
|
| Capillary Permeability | 1 | 2019 | 798 | 0.130 |
Why?
|
| Brain Infarction | 1 | 2017 | 299 | 0.130 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2017 | 712 | 0.130 |
Why?
|
| Cerebral Infarction | 1 | 2020 | 1011 | 0.130 |
Why?
|
| Eye Diseases | 1 | 2021 | 668 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2019 | 780 | 0.130 |
Why?
|
| Hyperalgesia | 1 | 2019 | 502 | 0.130 |
Why?
|
| Adiponectin | 1 | 2021 | 1101 | 0.120 |
Why?
|
| Neuroblastoma | 1 | 2022 | 1226 | 0.120 |
Why?
|
| Neurons | 3 | 2020 | 9336 | 0.120 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1880 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2021 | 1186 | 0.120 |
Why?
|
| Administration, Oral | 2 | 2020 | 3912 | 0.110 |
Why?
|
| Hemoglobins | 1 | 2019 | 1531 | 0.110 |
Why?
|
| Autophagy | 1 | 2020 | 1296 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2021 | 1161 | 0.110 |
Why?
|
| Cytoskeleton | 1 | 2017 | 1185 | 0.100 |
Why?
|
| Mice, Inbred Strains | 3 | 2021 | 1826 | 0.100 |
Why?
|
| Male | 18 | 2023 | 349776 | 0.100 |
Why?
|
| Memory | 1 | 2021 | 2173 | 0.100 |
Why?
|
| Ischemia | 1 | 2020 | 1907 | 0.100 |
Why?
|
| Cadherins | 1 | 2016 | 907 | 0.100 |
Why?
|
| Bone Marrow Cells | 1 | 2019 | 2509 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 1 | 2019 | 2764 | 0.090 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 850 | 0.090 |
Why?
|
| Anticonvulsants | 1 | 2020 | 1910 | 0.090 |
Why?
|
| Xanthophylls | 2 | 2020 | 96 | 0.090 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 1743 | 0.090 |
Why?
|
| Endothelium, Vascular | 2 | 2019 | 4459 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2014 | 1115 | 0.080 |
Why?
|
| Cell Line | 2 | 2019 | 15993 | 0.080 |
Why?
|
| Humans | 17 | 2023 | 743811 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 16674 | 0.070 |
Why?
|
| Blood Flow Velocity | 2 | 2021 | 1423 | 0.070 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 1980 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2281 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2020 | 3480 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2016 | 4026 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2016 | 10251 | 0.050 |
Why?
|
| Oxidative Stress | 3 | 2018 | 3082 | 0.050 |
Why?
|
| Rodentia | 1 | 2023 | 261 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2019 | 11478 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2021 | 419 | 0.050 |
Why?
|
| Rats | 3 | 2023 | 24250 | 0.050 |
Why?
|
| Mice, Inbred ICR | 1 | 2020 | 352 | 0.040 |
Why?
|
| Perfusion Imaging | 1 | 2021 | 195 | 0.040 |
Why?
|
| Papilledema | 1 | 2021 | 118 | 0.040 |
Why?
|
| Laboratories | 1 | 2023 | 462 | 0.040 |
Why?
|
| Maze Learning | 1 | 2021 | 478 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 8856 | 0.040 |
Why?
|
| Thrombin | 1 | 2021 | 598 | 0.040 |
Why?
|
| Larva | 1 | 2020 | 515 | 0.040 |
Why?
|
| Cell Movement | 2 | 2021 | 5216 | 0.040 |
Why?
|
| Retinal Neovascularization | 1 | 2021 | 244 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2021 | 637 | 0.040 |
Why?
|
| Motor Activity | 2 | 2020 | 2714 | 0.040 |
Why?
|
| Protoporphyrins | 1 | 2018 | 164 | 0.040 |
Why?
|
| Potassium | 1 | 2022 | 1336 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 1676 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2021 | 1159 | 0.040 |
Why?
|
| Receptors, Notch | 1 | 2022 | 739 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2016 | 424 | 0.030 |
Why?
|
| Heme Oxygenase-1 | 1 | 2018 | 381 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2018 | 595 | 0.030 |
Why?
|
| Nociceptors | 1 | 2019 | 432 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2020 | 1552 | 0.030 |
Why?
|
| Retinal Vessels | 1 | 2021 | 772 | 0.030 |
Why?
|
| Organelle Shape | 1 | 2014 | 2 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2019 | 1892 | 0.030 |
Why?
|
| Premedication | 1 | 2015 | 258 | 0.030 |
Why?
|
| Time Factors | 3 | 2021 | 40038 | 0.030 |
Why?
|
| Neuroimmunomodulation | 1 | 2016 | 157 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2017 | 689 | 0.030 |
Why?
|
| Protective Agents | 1 | 2015 | 156 | 0.030 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2017 | 362 | 0.030 |
Why?
|
| Brain Edema | 1 | 2018 | 617 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2022 | 5078 | 0.030 |
Why?
|
| Homeostasis | 1 | 2022 | 3337 | 0.020 |
Why?
|
| Retina | 1 | 2021 | 2612 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2021 | 3510 | 0.020 |
Why?
|
| Zebrafish | 1 | 2020 | 2995 | 0.020 |
Why?
|
| Gene Expression | 1 | 2021 | 7793 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 10940 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2016 | 2500 | 0.020 |
Why?
|
| Research Design | 1 | 2023 | 5983 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2017 | 8436 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2016 | 2922 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2014 | 1373 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 19894 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 15067 | 0.020 |
Why?
|
| Cognition | 1 | 2021 | 6759 | 0.010 |
Why?
|
| Disease Progression | 1 | 2020 | 13273 | 0.010 |
Why?
|
| Pain | 1 | 2019 | 4987 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 21824 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 12066 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 29777 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13691 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2021 | 63042 | 0.010 |
Why?
|
| Prognosis | 1 | 2014 | 29052 | 0.010 |
Why?
|
| Aged | 1 | 2022 | 163178 | 0.010 |
Why?
|
| Female | 1 | 2023 | 380020 | 0.000 |
Why?
|
Concepts
(177)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(7)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_